Effects of abciximab on the architecture of platelet-rich clots in patients with acute myocardial infarction undergoing primary coronary intervention

Circulation

Volumn 103, Issue 19, 2001, Pages 2328-2331

  Collet, J P ^a   Montalescot, G ^a   Lesty, C ^a   Mishal, Z ^b   Soria, J ^b   Choussat, R ^a   Drobinski, G ^a   Soria, C ^b   Pinton, P ^c,e   Barragan, P ^d   Thomas, D ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b HÔPITAL PAUL BROUSSE   (France)

^c Eli Lilly Company   (France)

^d Clinique Beauregard   (France)

^e ELI LILLY AND COMPANY   (United States)

Author keywords

Abciximab; Fibrin; Myocardial infarction; Platelets; Thrombosis

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; FLOW RATE; FOLLOW UP; HEART MUSCLE REPERFUSION; HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE AGGREGATION; THROMBOCYTE RICH PLASMA; VISCOELASTICITY;

EID: 14344270942     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.103.19.2328     Document Type: Article

References (11)

1. Gold HK, Garabedian HD, Dinsmore RE, et al. Restoration of coronary flow in myocardial infarction by intravenous chimeric 7E3 antibody without plasminogen activators. Circulation. 1997;95:1755-1759.
2. van den Merkhof LF, Ziljstra F, Olsson H, et al. Abciximab in the treatment of acute myocardial infarction eligible for primary percutaneous transluminal coronary angioplasty. J Am Coll Cardiol. 1999;33:1528-1532.
3. Antman EM, Giugliano RP, Gibson CM, et al. Abciximab facilitates the rate and extent of thrombolysis: results of the Thrombolysis In Myocardial Infarction (TIMI) 14 trial. Circulation. 1999;99:2720-2732.
4. The Speed Investigators. Trial of abciximab with and without low-dose reteplase for acute myocardial infarction. Circulation. 2000;101:2788-2794.
5. Collet JP, Montalescot G, Lesty C, et al. Disaggregation of in vitro pre-formed platelet-rich clots by abciximab increases fibrin exposure and promotes fibrinolysis. Arterioscler Thromb Vasc Biol. 2001;21: 142-148.
6. Janmey PA. A torsion pendulum for measurement of the viscoelasticity of biopolymers and its application to actin networks. J Biochem Biophys Methods. 1991;22:41-54.
7. Blombäck B, Carlsson K, Hessel B, et al. Native fibrin gel networks observed by 3D microscopy, permeation and turbidity. Biochim Biophys Acta. 1989;997:96-115.
8. Collet JP, Mishal Z, Vasse M, et al. Pharmacological approach of fibrin gel architecture modulation and thrombus degradation: its implication in atherogenesis and thromboembolism disease. Thromb Res. 1994;75: 355-359.
9. GUSTO Hb Angioplasty substudy Investigators. A clinical trial comparing primary angioplasty with tissue plasminogen activator for acute myocardial infarction. N Engl J Med. 1997;336:1621-1628.
10. Liem A, Zijlstra F, Ottervanger JP, et al. High dose heparin as pretreatment for primary angioplasty in acute myocardial infarction: the Heparin in Early Patency (HEAP) randomized trial. J Am Coll Cardiol. 2000;35:600-604.
11. Carr ME, Carr SL, Greilich PE. Heparin ablates force development during platelet mediated clot retraction. Thromb Haemost. 1996;75:674-678.